The present invention relates to a novel recombinant nanocage and use thereof wherein the nanocage is formed by self-assembly of a fusion protein including a phagocytosis enhancing protein and a self-assembling protein, and to a protein nanocage complex in which an immunogenic cell death inducer is loaded in the nanocage as an active ingredient.

The present invention relates to a novel recombinant nanocage and use thereof wherein the nanocage is formed by self-assembly of a fusion protein including a phagocytosis enhancing protein and a self-assembling protein, and to a protein nanocage complex in which an immunogenic cell death inducer is loaded in the nanocage as an active ingredient.

Aspects of the disclosure include materials and methods for the targeted delivery of growth factors, and other compounds that stimulate bone growth and in some aspect bone healing. Some aspects of the disclosure include methods for synthesizing and testing these compounds. Some aspects of the invention include methods of using the compounds disclosed herein to treat bone fractures and bone defects.

The targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein.

The targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein.

An isolated peptide comprises a motif of RRWQW (SEQ ID NO: 1) for melanin polymerization and hair darkening is provided. Also disclosed herein are methods and compositions for hair darkening in a mammal subject.

The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.

The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.

Aspects of the disclosure include material and methods for the targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein. Aspects of the disclosure can be used to treat bone fractures and bone defects.

A modified transferrin DNA binding domain. The transferrin is lactotransferrin (LTF), serotransferrin (TF), melanotransferrin (MTF) or ovotransferrin (OTF), and the N terminal of each transferrin has one homologous DNA binding domain, wherein the 10.sup.th site and 20.sup.th site of the DNA binding domain are C; and the amino acid sequence of the modified transferrin DNA binding domain is as follows: C in the 10.sup.th site and 20.sup.th site is replaced by other amino acids so that no disulfide bond can be formed. The present invention also discloses a recombinant DNA polymerase and a preparation method thereof. The preparation method comprises the step of coupling the modified transferrin DNA binding domain with a DNA polymerase. The present invention also discloses a PCR test kit containing the recombinant DNA polymerase.